Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale

Shunichi Homma, Marco R. DiTullio, Ralph L Sacco, Robert R. Sciacca, J. P. Mohr

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background and Purpose-Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic stroke patients with PFO. Methods-250 cryptogenic stroke patients from PICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic stroke patients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older). Results-Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95% CI, 0.02 to 1.78; 2-year event rates, 2.0% versus 9.3%; and P=0.70; hazard ratio=0.72; 95% CI, 0.14 to 3.73; 2-year event rates, 10.0% versus 13.9%). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95% CI, 1.33 to 7.75; 2-year event rates 37.9% versus 14.5%). Conclusions-In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.

Original languageEnglish
Pages (from-to)2145-2149
Number of pages5
JournalStroke
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Fingerprint

Patent Foramen Ovale
Stroke
Age Groups
Databases

Keywords

  • Aspirin
  • Echocardiography
  • Stoke
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. / Homma, Shunichi; DiTullio, Marco R.; Sacco, Ralph L; Sciacca, Robert R.; Mohr, J. P.

In: Stroke, Vol. 35, No. 9, 01.09.2004, p. 2145-2149.

Research output: Contribution to journalArticle

Homma, Shunichi ; DiTullio, Marco R. ; Sacco, Ralph L ; Sciacca, Robert R. ; Mohr, J. P. / Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. In: Stroke. 2004 ; Vol. 35, No. 9. pp. 2145-2149.
@article{ddb0e2d9249948a3b380f8a01ba8cfbe,
title = "Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale",
abstract = "Background and Purpose-Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic stroke patients with PFO. Methods-250 cryptogenic stroke patients from PICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic stroke patients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older). Results-Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95{\%} CI, 0.02 to 1.78; 2-year event rates, 2.0{\%} versus 9.3{\%}; and P=0.70; hazard ratio=0.72; 95{\%} CI, 0.14 to 3.73; 2-year event rates, 10.0{\%} versus 13.9{\%}). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95{\%} CI, 1.33 to 7.75; 2-year event rates 37.9{\%} versus 14.5{\%}). Conclusions-In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.",
keywords = "Aspirin, Echocardiography, Stoke, Warfarin",
author = "Shunichi Homma and DiTullio, {Marco R.} and Sacco, {Ralph L} and Sciacca, {Robert R.} and Mohr, {J. P.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1161/01.STR.0000135773.24116.18",
language = "English",
volume = "35",
pages = "2145--2149",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale

AU - Homma, Shunichi

AU - DiTullio, Marco R.

AU - Sacco, Ralph L

AU - Sciacca, Robert R.

AU - Mohr, J. P.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background and Purpose-Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic stroke patients with PFO. Methods-250 cryptogenic stroke patients from PICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic stroke patients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older). Results-Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95% CI, 0.02 to 1.78; 2-year event rates, 2.0% versus 9.3%; and P=0.70; hazard ratio=0.72; 95% CI, 0.14 to 3.73; 2-year event rates, 10.0% versus 13.9%). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95% CI, 1.33 to 7.75; 2-year event rates 37.9% versus 14.5%). Conclusions-In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.

AB - Background and Purpose-Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic stroke patients with PFO. Methods-250 cryptogenic stroke patients from PICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic stroke patients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older). Results-Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95% CI, 0.02 to 1.78; 2-year event rates, 2.0% versus 9.3%; and P=0.70; hazard ratio=0.72; 95% CI, 0.14 to 3.73; 2-year event rates, 10.0% versus 13.9%). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95% CI, 1.33 to 7.75; 2-year event rates 37.9% versus 14.5%). Conclusions-In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.

KW - Aspirin

KW - Echocardiography

KW - Stoke

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=4344694354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344694354&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000135773.24116.18

DO - 10.1161/01.STR.0000135773.24116.18

M3 - Article

C2 - 15232117

AN - SCOPUS:4344694354

VL - 35

SP - 2145

EP - 2149

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -